These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 22067390)
1. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822 [TBL] [Abstract][Full Text] [Related]
3. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968 [TBL] [Abstract][Full Text] [Related]
4. Common cancer stem cell gene variants predict colon cancer recurrence. Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173 [TBL] [Abstract][Full Text] [Related]
5. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. Yamanaka T; Oki E; Yamazaki K; Yamaguchi K; Muro K; Uetake H; Sato T; Nishina T; Ikeda M; Kato T; Kanazawa A; Kusumoto T; Chao C; Lopatin M; Krishnakumar J; Bailey H; Akagi K; Ochiai A; Ohtsu A; Ohashi Y; Yoshino T J Clin Oncol; 2016 Aug; 34(24):2906-13. PubMed ID: 27325854 [TBL] [Abstract][Full Text] [Related]
6. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335 [TBL] [Abstract][Full Text] [Related]
7. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Lyman GH; Cosler LE; Kuderer NM; Hornberger J Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307 [TBL] [Abstract][Full Text] [Related]
8. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725 [TBL] [Abstract][Full Text] [Related]
9. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406 [TBL] [Abstract][Full Text] [Related]
10. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. Venook AP; Niedzwiecki D; Lopatin M; Ye X; Lee M; Friedman PN; Frankel W; Clark-Langone K; Millward C; Shak S; Goldberg RM; Mahmoud NN; Warren RS; Schilsky RL; Bertagnolli MM J Clin Oncol; 2013 May; 31(14):1775-81. PubMed ID: 23530100 [TBL] [Abstract][Full Text] [Related]
11. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753 [TBL] [Abstract][Full Text] [Related]
12. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence. Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406 [TBL] [Abstract][Full Text] [Related]
13. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339 [TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028 [TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756 [TBL] [Abstract][Full Text] [Related]
16. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. Meyerhardt JA; Heseltine D; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Thomas J; Nelson H; Whittom R; Hantel A; Schilsky RL; Fuchs CS J Clin Oncol; 2006 Aug; 24(22):3535-41. PubMed ID: 16822843 [TBL] [Abstract][Full Text] [Related]
17. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118 [TBL] [Abstract][Full Text] [Related]
19. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812 [TBL] [Abstract][Full Text] [Related]
20. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]